Therapeutic effect of recombinant interferon alpha 2b combined with budesonide and ipratropium bromide on infantile bronchiolitis

Objective To study the effectiveness of recombinant interferon alpha 2b combined with budesonide and ipratropium bromide inhalation in the treatment of infantile bronchiolitis. Methods One hundred and thirty cases diagnosed with bronchiolitis in our hospital from September 2016 to September 2017 were randomly divided into observation group (n=66) and control group(n=64). Patients in observation group were treated with recombinant interferon alpha 2b inhalation combined with budesonide plus ipratropium bromide for 1 week, and the control group with routine anti-infection inhalation treatment. When symptoms of hypoxia appeared, oxygen inhalation was given in time. The signs, curative effect, syncytial virus RSV and hMPV infection of the two groups were observed and compared. Results In terms of asthma, time to cough disappearance and time to temperature returned to normal, patients in observation group were superior to the control group (2.29±0.63) d vs (3.52±0.80) d; (3.20±0.83) d vs (4.32±0.90) d; (18.0±2.5) h vs (27.2±2.5) h; all P< 0.05, and the total effective rate of the observation group was significantly higher than that of the control group (89.39% vs 70.31%, P< 0.05). There was no significant difference in serum RSV and hMPV levels between the two groups before treatment (all P> 0.05), while they were significantly lower in the observation group compared to those of the control group (0.48±0.07) mmol/L vs (0.83±0.20) mmol/L, P=0.000; (0.59±0.42) mmol/L vs (1.77±0.48) mmol/L, P=0.000. Conclusion Recombinant interferon alpha 2b combined with budesonide and ipratropium bromide is effective in treating children with bronchiolitis, which can effectively relieve the inflammation reaction and shorten the course of the disease.